Literature DB >> 9010882

Developments in antithrombotic therapy: state of the art anno 1996.

H ten Cate1, M T Nurmohamed, J W ten Cate.   

Abstract

This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9010882     DOI： 10.1007/bf00735960

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN： 0928-1231


  82 in total

1.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

Authors:  J M Maraganore; P Bourdon; J Jablonski; K L Ramachandran; J W Fenton
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

2.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

Authors:  E Skrzypczak-Jankun; V E Carperos; K G Ravichandran; A Tulinsky; M Westbrook; J M Maraganore
Journal:  J Mol Biol       Date:  1991-10-20       Impact factor: 5.469

3.  A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture.

Authors:  G Agnelli; B Cosmi; P Di Filippo; V Ranucci; F Veschi; M Longetti; C Renga; F Barzi; F Gianese; L Lupattelli
Journal:  Thromb Haemost       Date:  1992-02-03       Impact factor: 5.249

4.  Selective and nonselective inhibition of thromboxane formation.

Authors:  G A FitzGerald; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

5.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.

Authors:  M T Nurmohamed; F R Rosendaal; H R Büller; E Dekker; D W Hommes; J P Vandenbroucke; E Briët
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

6.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

7.  Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.

Authors:  I Fox; A Dawson; P Loynds; J Eisner; K Findlen; E Levin; D Hanson; T Mant; J Wagner; J Maraganore
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

8.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

9.  Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.

Authors:  J S Ginsberg; M T Nurmohamed; M Gent; B MacKinnon; J Sicurella; P Brill-Edwards; M N Levine; A A Panju; P Powers; P Stevens
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

10.  LY53857, a 5HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion.

Authors:  H C Wilson; W Coffman; A L Killam; M L Cohen
Journal:  Thromb Haemost       Date:  1991-09-02       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.